DelveInsight’s “Postoperative Nausea and Vomiting Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Postoperative Nausea and Vomiting pipeline landscapes.
The report comprises Postoperative Nausea and Vomiting pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Postoperative Nausea and Vomiting therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Postoperative Nausea and Vomiting pipeline products.
Postoperative Nausea and Vomiting Overview
Postoperative nausea and vomiting (PONV) is an enormous problem for patients recovering after surgery. About one-third of people experience vomiting, and half of them experience nausea. Nausea, retching, or vomiting usually occurs during the first 24–48 h after surgery in inpatients. Also, PONV is a common side effect following sedation and general anesthesia.
The consequences of PONV can include increased anxiety for future surgical procedures, increased recovery time and hospital stay, and in severe cases, aspiration pneumonia, incisional hernia or suture dehiscence, bleeding esophageal rupture, and metabolic alkalosis. The causes of the PONV are related to the patient and preoperative, intraoperative, and postoperative factors such as pharyngeal stimulation, opioid medication, hypoxia, hypertension, etc.
Some of the key takeaways from the Postoperative Nausea and Vomiting Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Cara Therapeutics, Camurus/Braeburn, etc., are developing therapies for the treatment of Postoperative Nausea and Vomiting.
-
Emerging therapies such as CR845 (difelikefalin), CAM2058, are expected to have a significant impact on the Postoperative Nausea and Vomiting market in the coming years.
Get an overview of pipeline landscape @ Postoperative Nausea and Vomiting Clinical Trials Analysis
Postoperative Nausea and Vomiting Pipeline Therapies along with Key Players:
-
CR845 (difelikefalin): Cara Therapeutics
-
CAM2058: Camurus/Braeburn
Scope of Postoperative Nausea and Vomiting Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Cara Therapeutics, Camurus/Braeburn, and others.
-
Pipeline Therapies: CR845 (difelikefalin), CAM2058, and others.
Table of Contents
|
1 |
Postoperative Nausea and Vomiting Report Introduction |
|
2 |
Postoperative Nausea and Vomiting Executive Summary |
|
3 |
Postoperative Nausea and Vomiting Overview |
|
4 |
Postoperative Nausea and Vomiting- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Postoperative Nausea and Vomiting Pipeline Therapeutics |
|
6 |
Postoperative Nausea and Vomiting Late Stage Products (Phase II/III) |
|
7 |
Postoperative Nausea and Vomiting Mid Stage Products (Phase II) |
|
8 |
Postoperative Nausea and Vomiting Early Stage Products (Phase I) |
|
9 |
Postoperative Nausea and Vomiting Preclinical Stage Products |
|
10 |
Postoperative Nausea and Vomiting Therapeutics Assessment |
|
11 |
Postoperative Nausea and Vomiting Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Postoperative Nausea and Vomiting Key Companies |
|
14 |
Postoperative Nausea and Vomiting Key Products |
|
15 |
Postoperative Nausea and Vomiting Unmet Needs |
|
16 |
Postoperative Nausea and Vomiting Market Drivers and Barriers |
|
17 |
Postoperative Nausea and Vomiting Future Perspectives and Conclusion |
|
18 |
Postoperative Nausea and Vomiting Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Postoperative Nausea and Vomiting Drugs Pipeline Report.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/